{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:23Z","timestamp":1756339403884,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1136\/dtb.2017.2.0452","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T20:25:18Z","timestamp":1486067118000},"page":"13-13","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Spironolactone\u2014potion or poison?"],"prefix":"10.1136","volume":"55","member":"239","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"2025082701364778000_55.2.13.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025082701364778000_55.2.13.2","first-page":"1393","article-title":"Spironolactone in left-sided heart failure: how does it fit in?","volume":"64","author":"Margo","year":"2001","journal-title":"Am Fam Physician"},{"issue":"(7)","key":"2025082701364778000_55.2.13.3","first-page":"2","article-title":"Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia","volume":"9","author":"Medicines and Healthcare products Regulatory Agency","year":"2016","journal-title":"Drug Safety Update"},{"key":"2025082701364778000_55.2.13.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2025082701364778000_55.2.13.5","unstructured":"National Institute for Health and Care Excellence, 2010. Chronic heart failure in adults (CG108) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/CG108 [Accessed 18 January 2017]."},{"key":"2025082701364778000_55.2.13.6","unstructured":"Aldactone 25mg tablets. Summary of product characteristics, UK. Pfizer Limited, March 2016."},{"key":"2025082701364778000_55.2.13.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"2025082701364778000_55.2.13.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731"},{"issue":"(5)","key":"2025082701364778000_55.2.13.9","first-page":"2","article-title":"Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia-clarification","volume":"10","author":"Medicines and Healthcare products Regulatory Agency","year":"2016","journal-title":"Drug Safety Update"},{"key":"2025082701364778000_55.2.13.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048144"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2017.2.0452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:36:55Z","timestamp":1756283815000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2017.2.0452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,9]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/dtb.2017.2.0452"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2017.2.0452","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}